The latest research results indicate that the new triple therapy comprising of amoxicillin, protein pump inhibitor (PPI) and levofloxacin has recorded the highest rate of eradication of this bacterial infection (Woo and Robinson, 2015). Alternatively known as hybrid therapy, it delays the overall duration of amoxicillin treatment for about 14 days (Woo and Robinson, 2015). Essentially, the prolonged treatment accounts for a significant percentage of H. pylori eradication by this hybrid therapy as well.
The prevalence resistance worldwide to the triple therapy has enhanced more effort on vonoprazan-based therapy, particularly in regions with a significantly limited rate of clarithromycin resistance. With the evolution of vonoprazan therapy, the treatment options and generally the eradication of helicobacter pylori problems are broadened (Chey et al, 2017). More profoundly, switching the vonoprazan as an acid blocker for H. pylori means that there is a chance for a further reassessment of the triple therapy. It equally improves the efficacy of triple therapy through a significant reduction to the resistance in clarithromycin as previously noted. Additionally, concomitant therapy has also been introduced for the reduction of the metronidazole resistance estimated to be about 50% in Asian countries (Woo and Robinson, 2015). Concomitant therapy implies using conventional antibiotics to reduce resistance levels in triple therapy.
Patients should be advised against consuming contaminated food, water, and other consumables. Such factors exacerbate bacterial infection on the walls of the small intestine through releasing toxins and enzymes. Furthermore, it is imperative that the patient is advised to seek proper counseling. In addition, the interventions can be employed in the control, prevention, and management of H. pylori. Supporting and emphasizing programs on patient’s compliance with drugs, specifically, pharmacists will result in an increase in the number of patients who will be taking medication. While antibiotics are recommended, patients should be watchful of the side effects and report immediately to the healthcare facilities (Woo and Robinson, 2015). Patients are also encouraged to seek for medical checkups frequently. The earlier detection and treatment for this infection will result in a better positive result, unlike the late time action.
Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017). ACG clinical guideline: treatment of Helicobacter pylori infection. The American journal of gastroenterology, 112(2), 212.
Woo, T. M., & Robinson, M. V. (2015). Pharmacotherapeutics for advanced practice nurse prescribers. FA Davis.